Every Form 4 that TransMedics Group, Inc. (TMDX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TMDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TMDX filings page.
TransMedics Group, Inc. (TMDX) director David Weill purchased 1,336 shares of common stock in an open-market or private transaction on September 11, 2026 at $81.63 per share. Following this transaction, he directly holds 16,392 shares of TransMedics common stock. No Rule 10b5-1 trading plan is reported for this purchase.
TransMedics Group, Inc. director James R. Tobin reported a bona fide gift transfer of 18,000 shares of common stock on 2026-08-17 from an indirect holding titled "The Tobin 2024 Family Trust," leaving that trust with 0 shares. Following this reporting, Tobin holds 6,981 shares of TransMedics common stock directly and 155,146 shares indirectly through the "James R. Tobin 2012 Trust."
TransMedics Group, Inc. officer Nicholas Corcoran reported equity compensation awards. He received 11,727 restricted stock units (RSUs), each representing a contingent right to one share of common stock, bringing his direct common stock holdings to 41,558 shares.
He was also granted a stock option for 17,784 shares of common stock at an exercise price of $71.23 per share, expiring on July 10, 2036. The option vests at 2.0833% per month starting after April 10, 2026 and is scheduled to be fully vested by April 10, 2030, subject to continued service.
Hernandez Gerardo reported acquisition or exercise transactions in this Form 4 filing.
TransMedics Group, Inc. Chief Financial Officer Gerardo Hernandez received equity awards on 2026-07-10 consisting of 17,246 RSUs, each representing one share of common stock, and stock options for 26,153 shares at $71.23 per share, vesting monthly from April 10, 2026 through April 10, 2030. Following these grants, he holds 31,935 common shares directly and 26,153 options expiring July 10, 2036.
Hassanein Waleed H reported acquisition or exercise transactions in this Form 4 filing.
TransMedics Group President & CEO Waleed H. Hassanein received equity awards on July 10, 2026, including 49,669 restricted stock units and stock options for 112,984 shares at $71.23 per share, vesting monthly from April 2026 to April 2030.
Following these awards, he holds 171,093 shares directly and options on 112,984 shares, plus indirect holdings of 150,000 shares through the Hassanein 2026 Qualified Annuity Trust and 345,009 shares through the Waleed H. Hassanein Revocable Trust; a 150,000‑share transfer between these trusts was a change in the form of beneficial ownership exempt under Rule 16a-13.
TransMedics Group director Thomas J. Gunderson exercised stock options to acquire 19,285 shares of common stock at an exercise price of $2.21 per share on June 15, 2026. On the same date he sold 9,624 shares at $75.06 per share, and after these transactions he directly holds 16,642 common shares. A contextual note states that shares sold were used to cover the option exercise price and related tax withholding obligations.
Lovell Stephanie reported acquisition or exercise transactions in this Form 4 filing.
TransMedics Group, Inc. director Stephanie Lovell received an equity award in the form of restricted stock units. On May 20, 2026, she was granted 2,922 shares of common stock at a price of $0.00 per share as a compensation-related award, not an open-market purchase. Each restricted stock unit represents a contingent right to receive one share of TransMedics common stock. Following this grant, Lovell directly holds 5,788 shares of the company’s common stock.
Weill David reported acquisition or exercise transactions in this Form 4 filing.
TransMedics Group, Inc. director David Weill reported an equity compensation grant of 2,922 shares of common stock in the form of restricted stock units. Each RSU represents a contingent right to receive one share of common stock, with no cash paid per share. Following this award, Weill directly holds 15,056 shares of TransMedics common stock, reflecting a routine compensation-related increase in his ownership rather than an open-market purchase.
RAINES MERILEE reported acquisition or exercise transactions in this Form 4 filing.
TransMedics Group director Merilee Raines received an equity grant of 2,922 restricted stock units (RSUs) on common stock. These RSUs are a form of stock-based compensation, with each unit representing the right to receive one TransMedics common share. Following this award, Raines directly holds 6,981 common shares.
Gunderson Thomas J. reported acquisition or exercise transactions in this Form 4 filing.
TransMedics Group, Inc. director Thomas J. Gunderson received an equity award of 2,922 restricted stock units. These RSUs were granted at no cash cost and each unit represents the right to receive one share of common stock. Following this grant, he directly holds 6,981 shares and RSUs in total, reflecting routine, compensation-related ownership rather than an open-market purchase or sale.
Basile Edward M reported acquisition or exercise transactions in this Form 4 filing.
TransMedics Group, Inc. director Edward M. Basile received a grant of 2,922 shares of common stock in the form of restricted stock units. The award was made at no cash cost per share and is a form of equity compensation. Following this grant, Basile directly holds 5,788 shares of the company’s common stock, showing his stake has increased through stock-based awards rather than open-market purchases or sales.
TOBIN JAMES R reported acquisition or exercise transactions in this Form 4 filing.
TransMedics Group, Inc. director James R. Tobin reported an equity award rather than an open-market trade. He received 2,922 restricted stock units, each representing a contingent right to one share of common stock at no cash cost. Following this grant, he holds 6,981 shares directly, in addition to indirect holdings reported as 18,000 shares held by The Tobin 2024 Family Trust and 155,146 shares held by the James R. Tobin 2012 Trust.
TransMedics Group director Edwin Kania reported a new equity award. On May 20, 2026, he received 2,922 restricted stock units, each representing one share of common stock. This is a compensation-related grant at $0.00 per share, not an open‑market purchase.
After the grant, Kania directly holds 263,732 common shares and indirectly holds 46,142 shares through Kania 2021 GRAT B. The filing shows no sales or option exercises, so the activity reflects an incremental increase in his overall ownership stake.
TransMedics Group, Inc. reported that company officer Matthew S. Forsyth received equity compensation on May 19, 2026. He was granted 15,409 restricted stock units, each representing one share of common stock, and a stock option for 23,171 shares of common stock at an exercise price of $66.13 per share. The option expires on March 9, 2036 and vests 25% on March 9, 2027, with the remainder vesting in equal monthly installments over the following three years, subject to continued service. These awards increase his direct equity stake and align his compensation with the company’s share performance.
TransMedics Group, Inc. director Stephanie Lovell reported an open-market sale of common stock. On March 4, 2026, she sold 1,193 shares of TransMedics common stock at a price of $149.62 per share. After this transaction, she directly owned 2,866 shares of the company’s common stock.
TransMedics Group, Inc. director David Weill reported an option exercise and related share sale. On March 4, 2026, he exercised a stock option for 3,571 shares of common stock at $14.20 per share after the derivative security was fully vested. He then sold 3,571 shares of common stock in an open-market transaction at a price of $146.82 per share. After these transactions, he directly owned 12,134 shares of common stock and held 1,429 stock option shares.
TransMedics Group Chief Financial Officer Gerardo Hernandez reported both option exercises and share sales. On March 4, 2026, he exercised stock options that delivered 7,236 shares of common stock and, together with earlier activity, sold a total of 7,611 shares. Some of the shares were sold to satisfy tax withholding obligations tied to restricted stock unit vesting through a sell-to-cover transaction. Reported sale prices reflect a weighted average around $147.21 per share, based on multiple trades between $147.14 and $147.47. After these transactions, he directly held 14,689 TransMedics common shares.
TransMedics Group, Inc. insider Anil P. Ranganath reported an automatic sale of common stock tied to tax withholding on vested restricted stock units. On March 2, 2026, he sold 864 shares at $139.12 per share in an open-market transaction designated as a “sell to cover” for required tax obligations. After this sale, he directly held 13,091 common shares, so the transaction reflects tax-related share disposition rather than a discretionary reduction of his overall stake.
TransMedics Group executive Nicholas Corcoran reported share transactions linked to restricted stock unit vesting. On March 2, 2026, he executed an open-market sale of 2,966 shares of common stock at $139.12 per share, leaving him with 29,831 shares held directly.
Earlier, on January 23, 2026, 984 shares at $135.30 per share were disposed of to satisfy tax withholding obligations upon RSU vesting. Footnotes state both the issuer’s share withholding and the “sell to cover” sale were required to cover Corcoran’s tax liabilities tied to these equity awards.
TransMedics Group, Inc. Chief Commercial Officer Giovanni Cecere reported equity awards consisting of stock options and restricted stock units. He was granted options to purchase 16,734 shares of common stock at an exercise price of $0.00 per share and 11,082 restricted stock units, each representing one share of common stock.
The option award vests as to 25% of the underlying shares on February 18, 2027, with the remaining shares vesting in equal monthly installments over the following three years, subject to continued service. The RSU grant reflects additional direct equity-based compensation tied to the company’s stock.
TransMedics Group, Inc. (TMDX) reported an insider equity transaction by its Senior Vice President, General Counsel and Secretary. On 11/25/2025, the officer exercised a stock option for 3,000 shares of common stock at an exercise price of $93.88 per share and then sold 3,000 shares of common stock at a weighted average price of $145.22 per share. After these transactions, the officer beneficially owned 13,955 shares of TransMedics common stock directly and held 7,420 stock options directly. The option referenced vested 25% on June 5, 2024 and will continue to vest in equal monthly installments over three years thereafter, subject to continued service.
TransMedics Group, Inc. (TMDX) President & CEO and director Waleed H. Hassanein reported an open-market purchase of company stock. On 11/17/2025, a related revocable trust acquired 8,775 shares of TransMedics common stock at a price of $114 per share. Following this transaction, the trust held 495,009 shares indirectly, while 121,424 shares were held directly in his name. This filing reflects an increase in the insider’s total beneficial ownership of TransMedics shares.
TransMedics Group (TMDX) Form 4: A director exercised 4,142 stock options at $0.70 on 10/29/2025 and sold 4,142 common shares at $130.45 the same day under a Rule 10b5-1 trading plan entered on November 6, 2024. After these transactions, the director directly owned 2,866 shares. The option was fully vested and carried a stated expiration of 02/16/2026, with zero derivative securities remaining afterward.